| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/05/2007 | EP1828203A2 Rapamycin derivatives and the uses thereof in the treatment of neurological disorders |
| 09/05/2007 | EP1828202A2 Rapamcyin analogues and the uses thereof in the treatment of neurologial proliferative and inflammatory disorders |
| 09/05/2007 | EP1828201A2 Macrocyclic quinazoline derivatives and their use as mtki |
| 09/05/2007 | EP1828200A1 Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer's disease. |
| 09/05/2007 | EP1828199A1 Thieno-pyridine derivatives as gaba-b allosteric enhancers |
| 09/05/2007 | EP1828197A1 NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE |
| 09/05/2007 | EP1828194A1 Tetracyclic imidazo-benzodiazepines as gaba receptors modulators |
| 09/05/2007 | EP1828189A1 Substituted pteridines for treating inflammatory diseases |
| 09/05/2007 | EP1828188A1 Bridged ring nk1 antagonists |
| 09/05/2007 | EP1828187A2 Crystalline forms of a factor xa inhibitor |
| 09/05/2007 | EP1828186A1 Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| 09/05/2007 | EP1828185A2 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors |
| 09/05/2007 | EP1828184A1 [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
| 09/05/2007 | EP1828183A1 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
| 09/05/2007 | EP1828182A2 Therapeutic pyrazolo[3,4-b]pyridines and indazoles |
| 09/05/2007 | EP1828181A2 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors |
| 09/05/2007 | EP1828180A1 1h-pyrrolo[2,3-beta]pyridines |
| 09/05/2007 | EP1828179A2 Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| 09/05/2007 | EP1828178A1 Process for preparation of high-purity meloxicam and meloxicam potassium salt |
| 09/05/2007 | EP1828177A2 Novel mch receptor antagonists |
| 09/05/2007 | EP1828176A1 Tetrahydroquinoline analogues as muscarinic agonists |
| 09/05/2007 | EP1828174A1 Azabicyclic muscarinic receptor antagonists |
| 09/05/2007 | EP1828173A1 Enentiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors |
| 09/05/2007 | EP1828172A1 Pyrrole derivatives having crth2 receptor antagonist activity |
| 09/05/2007 | EP1828169A2 Urea inhibitors of map kinases |
| 09/05/2007 | EP1828167A2 Acrylamide derivatives as antibiotic agents |
| 09/05/2007 | EP1828166A1 Hydantoin derivatives useful as metalloproteinase inhibitors |
| 09/05/2007 | EP1828165A1 Novel aminopyridine derivatives having aurora a selective inhibitory action |
| 09/05/2007 | EP1828163A2 Azole derivatives with antimuscarinic activity |
| 09/05/2007 | EP1828162A1 Tetrazolyl-methylene amino acid derivatives |
| 09/05/2007 | EP1828160A1 Sulfonyl amino cyclic derivatives and use thereof as mmp inhibitors |
| 09/05/2007 | EP1828156A2 N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto |
| 09/05/2007 | EP1828155A2 Diuretic compounds comprising heterocyclic nitric oxide donor groups,compositions and methods of use |
| 09/05/2007 | EP1828154A1 Phenyl-piperazin methanone derivatives |
| 09/05/2007 | EP1828151A2 Malonamide derivatives as inhibitors of gamma-secretase for the treatment of alzheimer's disease |
| 09/05/2007 | EP1828149A1 Method for the production of oxazoles by condensing aromatic aldehydes with a-ketoximes to n-oxides and then reacting the same with activated acid derivatives |
| 09/05/2007 | EP1828148A1 Triazole substituted aminobenzophenone compounds |
| 09/05/2007 | EP1828147A1 Quinoxalines as b-raf inhibitors |
| 09/05/2007 | EP1828146A1 Substituted n-heterocyclic compounds and their use as dopamine d3 receptor ligands |
| 09/05/2007 | EP1828145A2 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation |
| 09/05/2007 | EP1828144A2 Integrin antagonists useful as anticancer agents |
| 09/05/2007 | EP1828143A1 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors |
| 09/05/2007 | EP1828141A1 A one-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1h-imidazole-1-yl)methyl]-4h-carbazol-4-o |
| 09/05/2007 | EP1828138A1 Dpp-iv inhibitors |
| 09/05/2007 | EP1828137A1 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments |
| 09/05/2007 | EP1828136A1 (5s) -3-[(s)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as cetp inhibitors |
| 09/05/2007 | EP1828135A2 Compounds and compositions as modulators of steroidal receptors and calcium channel activities |
| 09/05/2007 | EP1828134A1 Piperazinyl pyridine derivatives as anti-obesity agents |
| 09/05/2007 | EP1828133A2 Methylene inhibitors of matrix metalloproteinase |
| 09/05/2007 | EP1828131A1 Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them |
| 09/05/2007 | EP1828130A2 Heterocycloalkyl-benzyl substituted hydroxyethlamines |
| 09/05/2007 | EP1828126A1 Acid addition salts of muscarinic receptor antagonists |
| 09/05/2007 | EP1828124A1 Biaromatic compounds that modulate ppar type receptors, process for preparing them and use thereof in cosmetic or pharmaceutical compositions |
| 09/05/2007 | EP1828123A1 Indolinones and their use as antiproliferative agents |
| 09/05/2007 | EP1828122A2 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| 09/05/2007 | EP1828121A2 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| 09/05/2007 | EP1828119A1 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| 09/05/2007 | EP1828118A1 Parp inhibitors |
| 09/05/2007 | EP1828115A2 2-methylene-19-nor-(20s)-1alpha-hydroxy-trishomopregnacalciferol |
| 09/05/2007 | EP1828114A2 17,20(e)-dehydro vitamin d analogs and their uses |
| 09/05/2007 | EP1828113A2 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses |
| 09/05/2007 | EP1828112A1 Amine salts of (-)-2-((2-(4-hydroxyphenyl)ethyl)thio)-3-(4-(2-(4-((methylsulfonyl)oxy)phenoxy)ethyl)phenyl)propanoic acid |
| 09/05/2007 | EP1828111A2 Methods and fluorinated compositions for treating amyloid-related diseases |
| 09/05/2007 | EP1828110A1 Process for the preparation of tamsulosin and intermediates thereof |
| 09/05/2007 | EP1828109A2 Guanidine derivatives as inhibitors of ddah |
| 09/05/2007 | EP1828107A1 Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use |
| 09/05/2007 | EP1828103A2 Manufacture process of n-substituted salicylamides |
| 09/05/2007 | EP1828100A1 Pharmaceutical compounds and compositions |
| 09/05/2007 | EP1828098A1 Crystal forms of cinacalcet hci and processes for their preparation |
| 09/05/2007 | EP1827606A2 Aryl amide sphingosine 1-phosphate analogs |
| 09/05/2007 | EP1827604A1 Methods and compositions for adoptive immunotherapy |
| 09/05/2007 | EP1827603A2 Novel pharmaceutical composition containing at least one dolastatin 10 derivative |
| 09/05/2007 | EP1827602A1 Modulating retinal pigmented epithelium permeaion by inhibiting or activating vegfr-1 |
| 09/05/2007 | EP1827500A2 Pegylated liposomal doxorubicin in combination with ecteinescidin 743 |
| 09/05/2007 | EP1827498A2 Stabilisation of glucocorticoid esters with acids |
| 09/05/2007 | EP1827497A2 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 09/05/2007 | EP1827495A2 Painkilling association comprising a dihydroimidazopyrazine derivative |
| 09/05/2007 | EP1827488A1 Composition comprising phosphatidyl serine and an antigen or allergen and the use thereof |
| 09/05/2007 | EP1827474A2 Heat shock proteins (hsp) and supraventricular arrhythmia |
| 09/05/2007 | EP1827468A2 Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer's disease |
| 09/05/2007 | EP1827467A2 Methods for use of oral care compositions containing free-b-ring flavonoid anti-oxidants |
| 09/05/2007 | EP1827463A1 Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia |
| 09/05/2007 | EP1827462A1 An implant for intraocular drug delivery |
| 09/05/2007 | EP1827461A1 Cladribine regimen for treating multiple sclerosis |
| 09/05/2007 | EP1827460A1 Nucleosides with antiviral and anticancer activity |
| 09/05/2007 | EP1827459A2 Therapeutic antisense oligonucleotide composition for the treatment of inflammatory bowel disease |
| 09/05/2007 | EP1827458A2 Selective inhibition of rock 1 in cardiac therapy |
| 09/05/2007 | EP1827457A1 Uridine derivatives as antiviral drugs against a flaviviridae, especially hcv |
| 09/05/2007 | EP1827456A1 Use of phospholipids for wound healing |
| 09/05/2007 | EP1827455A1 Novel formulation of pyridoxal 5'-phosphate and method of preparation |
| 09/05/2007 | EP1827453A1 Sulfonylurea compositions and a process for its preparation |
| 09/05/2007 | EP1827452A2 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol |
| 09/05/2007 | EP1827451A1 Use of a cyclopentenone prostaglandin for delaying for the onset and/or preventing the continuation of labour |
| 09/05/2007 | EP1827450A2 Methods for reducing the side effects associated with mirtazapine treatment |
| 09/05/2007 | EP1827449A2 The use of novel antibacterial compounds |
| 09/05/2007 | EP1827448A1 Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors |
| 09/05/2007 | EP1827447A1 Pyrimidine compounds and uses thereof |
| 09/05/2007 | EP1827446A2 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
| 09/05/2007 | EP1827445A2 Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists |
| 09/05/2007 | EP1827444A2 Mnk1 or mnk2 inhibitors |